Bio-Rad Laboratories Class B
BIO.B
12 hedge funds and large institutions have $82.4M invested in Bio-Rad Laboratories Class B in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.
0% more capital invested
Capital invested by funds: $82.3M → $82.4M (+$60.1K)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.03% less ownership
Funds ownership: 2.18% → 2.15% (-0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$151K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$32.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Tikvah Management
Charlotte,
North Carolina
|
-$1,000K |
| 2 |
Renaissance Technologies
New York
|
-$74.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TM
1
Tikvah Management
Charlotte,
North Carolina
| $73.3M | -$1,000K | -1,340 | -1% |
|
|
CL
2
CSS LLC
Chicago,
Illinois
| $5.57M | – | – | – |
|
|
3
Renaissance Technologies
New York
| $1.59M | -$74.6K | -100 | -4% |
|
4
Morgan Stanley
New York
| $522K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $374K | +$32.8K | +44 | +10% |
|
|
GI
6
GAMCO Investors
Greenwich,
Connecticut
| $234K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $226K | +$151K | +202 | +208% |
|
|
OPCM
8
Osborne Partners Capital Management
San Francisco,
California
| $214K | – | – | – |
|
|
GAM
9
Gemmer Asset Management
Walnut Creek,
California
| $211K | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $42K | – | – | – |
|
11
Osaic Holdings
Scottsdale,
Arizona
| $39K | – | – | – |
|
12
Bank of America
Charlotte,
North Carolina
| $29K | – | – | – |
|
BIO.B Hedge Fund Activity: Q4 2021 in Review
12 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q4 2021, worth a combined $82.4M — up 0.07% from $82.3M a quarter earlier.
Fund positioning in BIO.B was balanced in Q4 2021: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $151K. The largest seller was Tikvah Management, cutting an estimated $1,000K.
- 12 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $82.4M of Bio-Rad Laboratories Class B stock for Q4 2021, up 0.07% quarter-over-quarter.
- 0 funds opened new Bio-Rad Laboratories Class B positions in Q4 2021 and 0 closed out.
- The largest Bio-Rad Laboratories Class B buyer in Q4 2021 was UBS Group, an estimated $151K added.
- The largest Bio-Rad Laboratories Class B seller in Q4 2021 was Tikvah Management, an estimated $1,000K sold.
Based on aggregated 13F filings for Q4 2021.